Samuel Etchie, MD
Psychiatry · la Mesa, CANPI 1124039052
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,909 of the $74,249 with a category attached, or 72.6%. 16 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 58.4% of the total. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 370 payments — averaging $200.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$43K
- AbbVie$15K
- Neurocrine Biosciences, Inc.$6K
- Alkermes, Inc.$3K
- Sunovion Pharmaceuticals Inc.$2K
- Acadia Pharmaceuticals Inc$880
- plus $4K from 10 others
Across 3 payments — averaging $4360.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$13K
What the payments were for
- Consulting fees$4,0405%
- Speaking & faculty fees$53,90973%
- Travel & lodging$2,7384%
- Food & beverage$13,18818%
- Education$3751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 103 | $43,324 |
| AbbVie(2 entities) | 35 | $14,986 |
| Neurocrine Biosciences, Inc. | 17 | $6,141 |
| Alkermes, Inc. | 75 | $3,041 |
| Sunovion Pharmaceuticals Inc. | 46 | $1,505 |
| Acadia Pharmaceuticals Inc | 15 | $880 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $744 |
| Otsuka America Pharmaceutical, Inc. | 9 | $703 |
| E.r. Squibb & Sons, L.L.C. | 27 | $589 |
| Axsome Therapeutics, Inc. | 6 | $584 |
| Vanda Pharmaceuticals Inc. | 7 | $572 |
| Johnson & Johnson | 5 | $543 |
| Neuronetics, Inc. | 5 | $384 |
| Avanir Pharmaceuticals, Inc. | 1 | $126 |
| Indivior Inc. | 4 | $91 |
| Lundbeck LLC | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$33,263
- VRAYLAR$14,660
- INGREZZA$6,024
- LYBALVI$3,385
- AUSTEDO$2,968
- ARISTADA$2,800
- ARISTADA INITIO$588
- Auvelity$584
- LATUDA$545
- Fanapt$492
- CAPLYTA$488
- INVEGA SUSTENNA$413
- REXULTI$391
- COBENFY$380
- NUPLAZID$233
- ABILIFY MAINTENA$233
- NUEDEXTA$126
- SPRAVATO$125
- ABILIFY ASIMTUFII$111
How this compares
$74,249 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 261 | $681,087 |
| Abilify MaintenaAripiprazole | 49 | $130,537 |
| AristadaAripiprazole Lauroxil | 27 | $60,318 |
| Chlorpromazine Hcl | 180 | $55,158 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $49,142 |
| UzedyRisperidone | 15 | $25,200 |
| Risperdal ConstaRisperidone Microspheres | 26 | $25,165 |
| Divalproex Sodium | 326 | $17,420 |
| Quetiapine Fumarate | 776 | $15,846 |
| Lurasidone Hcl | 126 | $13,710 |
| Aripiprazole | 169 | $13,426 |
| Clozapine | 202 | $12,268 |
| Olanzapine | 595 | $12,043 |
| Olanzapine OdtOlanzapine | 133 | $11,613 |
| RexultiBrexpiprazole | 15 | $10,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $543 | $706,252287 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $703 | $141,46264 claims |
| Alkermes, Inc.Aristada, Lybalvi | $3,041 | $109,45955 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $43,324 | $25,20015 claims |
| AbbVieLexapro | $14,986 | $5,36912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in la Mesa
- Brian Millerla Mesa$146K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.